GlassScriptPhysician profile
Michael L Broussard
NPI 1699890376
$16,809.66
in general payments reported to CMS, 2019-2025
83 companies · $3,434 in 2025
The $3,434 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,215 · 2020: $729 · 2021: $1,940 · 2022: $2,839 · 2023: $2,674 · 2024: $2,979 · 2025: $3,434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,914 · Education: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,913.63 |
| Education | $172.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,294.47 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,281.44 | 2019-2025 | Calquence, Imfinzi, Enhertu |
| Merck Sharp & Dohme LLC | $913.17 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Amgen INC. | $796.60 | 2019-2025 | Kyprolis, Imdelltra (Amg757), Kyprolis |
| Celgene Corporation | $775.21 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $758.39 | 2019-2025 | Opdivo, Opdualag |
| Pfizer INC. | $720.97 | 2019-2025 | |
| Astellas Pharma US INC | $672.29 | 2019-2025 | Padcev, Vyloy, Xtandi |
| Daiichi Sankyo INC. | $608.17 | 2020-2025 | Enhertu, Datroway, Injectafer |
| Janssen Biotech, INC. | $592.43 | 2019-2025 | Darzalex, Tecvayli, Imbruvica |
| Eisai INC. | $520.42 | 2019-2025 | |
| Lilly USA, LLC | $516.87 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $492.23 | 2019-2025 | Alunbrig, Ninlaro, Fruzaqla |
| Genentech USA, INC. | $452.99 | 2019-2025 | Polivy, Columvi, Lunsumio |
| Genzyme Corporation | $450.93 | 2019-2025 |
Show all 83 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Broussard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.